Simple blood draw could replace invasive biopsies for cervical cancer
NCT ID NCT05606133
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study is testing a blood test called NavDx that looks for tiny pieces of HPV DNA shed by cancer cells. The goal is to see if this simple blood draw can accurately detect cervical cancer and precancer, and monitor how patients respond to treatment. The study will enroll 100 women with HPV-related cervical dysplasia or cervical cancer.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- NavDx blood test
- What this could lead to
- If successful, this blood test could provide a simple, non-invasive way to screen for and monitor cervical cancer and precancer, reducing the need for biopsies and other invasive procedures.
- What could go wrong
- This is a small pilot study with only 100 participants, so results may not apply to everyone. The test may not reliably distinguish between precancer and invasive cancer, and further larger studies are needed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 100 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Aug 2022
- Expected to finish
-
Aug 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: All patients above age 18, with biopsy proven HPV-related high-grade cervical dysplasia or invasive cervical cancer will be included. Exclusion Criteria: Persons who do not meet the above inclusion criteria.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cervical cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Lenox Hill Hospital
RECRUITINGNew York, New York, 10075, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can pulsed radiation extend life in metastatic cervical cancer?
- Robotic surgery vs standard approaches: does the platform change cancer outcomes?
- New antibody aims to preserve immune checkpoint while fighting cancer
- Smart speculum could bring cervical cancer screening to remote areas
- Your gut bacteria may hold the key to whether immunotherapy works
- Amazon plant put to the test against Cancer's relentless tiredness